Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13601621 | 1.00 | TSHR (0.56) | TSHRSMN1; SMN2TP53KMT2ACA14 | |
| SCHEMBL10295990 | 1.00 | TSHR (0.56) | TSHRSMN1; SMN2TP53KMT2ACA14 | |
| SCHEMBL29051545 | 0.97 | TSHR (0.53) | TSHRSMN1; SMN2TP53KMT2ACA14 | |
| Ammonia Solution, Strong SCHEMBL21219106 | 0.97 | TSHR (0.53) | TSHRSMN1; SMN2TP53KMT2ACA14 | |
| Butanedione SCHEMBL11722429 | 0.93 | TSHR (0.48) | TSHRSMN1; SMN2TP53KMT2ACA14 | |
| Water SCHEMBL28077825 | 0.93 | TSHR (0.48) | TSHRSMN1; SMN2TP53KMT2ACA14 | |
| SCHEMBL590895 | 0.88 | SMN1; SMN2 (0.50) | TSHRSMN1; SMN2KMT2ACA14CA12 | |
| SCHEMBL13266324 | 0.88 | SMN1; SMN2 (0.50) | TSHRSMN1; SMN2KMT2ACA14CA12 | |
| SCHEMBL6064611 | 0.88 | SMN1; SMN2 (0.50) | TSHRSMN1; SMN2KMT2ACA14CA12 | |
| SCHEMBL590894 | 0.88 | SMN1; SMN2 (0.50) | TSHRSMN1; SMN2KMT2ACA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 497 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724307-B1 | LAUNDRY SURFACTANTS HAVING INHERENT BUILDING CAPACITY DERIVED FROM BIO-BASED HYDROYACIDS AND EPOXIDES; AND PROCESS THEREFORE | BATTELLE MEMORIAL INSTITUTE (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2024077407-A1 | CHIRAL REDUCING AGENT AND METHOD FOR SYNTHESIZING CHIRAL NICOTINE | 成都化润药业有限公司 | 2024-04-18 | — | — | WO | claimed |
| CN-117480174-A | Chiral reducing agent and method for synthesizing chiral nicotine | 成都化润药业有限公司 | 2024-01-30 | — | — | CN | claimed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | claimed |
| CN-117064626-A | Medical hydrogel patch | 浙江银达生物技术有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-116849913-A | Manufacturing method of medical hydrogel patch | 浙江银达生物技术有限公司 | 2023-10-10 | — | — | CN | claimed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | claimed |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | claimed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | claimed |
| US-20220275314-A1 | GLYCEROL BASED DETERGENT BUILDERS AND ADDITIVES | BATTELLE MEMORIAL INSTITUTE | 2022-09-01 | — | — | US | claimed |
| EP-1536291-A1 | REMOVING SOLUTION | Daikin Industries, Ltd. (JP) | 2005-06-01 | — | — | EP | claimed |
| US-20050016733-A1 | Well treatment fluid compositions and methods for their use | COMBINED SYSTEMS, INC. | 2005-01-27 | — | — | US | claimed |
| US-20020125012-A1 | Well treatment fluid compositions and methods for their use | BJ SERVICES COMPANY | 2002-09-12 | — | — | US | claimed |
| WO-2002055843-A1 | WELL TREATMENT FLUID COMPOSITIONS AND METHODS FOR THEIR USE | BJ SERVICES COMPANY (US) | 2002-07-18 | — | — | WO | claimed |
| CN-1203224-A | Process for preparation of (1S,2R)-1-amino-2-indanol-(R,R)-tartrate methanol solvate | DSM NV (NL) | 1998-12-30 | — | — | CN | claimed |
| EP-0540654-B1 | LOW FRICTION SEAL ASSEMBLY | MATHER SEAL CO (US) | 1995-01-11 | — | — | EP | claimed |
| EP-0540654-A1 | LOW FRICTION SEAL ASSEMBLY. | MATHER SEAL CO (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001881-A1 | LOW FRICTION SEAL ASSEMBLY | MATHER SEAL COMPANY (US) | 1992-02-06 | — | — | WO | claimed |
| US-5015001-A | Low friction seal assembly | MATHER SEAL COMPANY (US) | 1991-05-14 | — | — | US | claimed |
| US-4059463-A | Process for producing ferromagnetic powder | FUJI PHOTO FILM CO., LTD. (JA) | 1977-11-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | TSHR 3315/4885SMN1; SMN2 1547/4885TP53 4755/4885 |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | TSHR 3315/4885SMN1; SMN2 1547/4885TP53 4755/4885 |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | TSHR 3315/4885SMN1; SMN2 1547/4885TP53 4755/4885 |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | TSHR 3315/4885SMN1; SMN2 1547/4885TP53 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.